London, UK – Prokarium starts 2019 with move to London Bioscience Innovation Centre (LBIC) to join the growing biotech community in London’s Knowledge Quarter. Prokarium, which is focused on the development of novel vaccines against infectious diseases and immunotherapy for treatment of solid tumours, has moved into its new headquarters to the London Bioscience Innovation Centre and will occupy both laboratory and office space. Following its recent $10m fundraising round led by Riyadh Valley Company, Prokarium will be growing rapidly over the course of 2019, with a total of 20 staff expected to be working at the company by the end of the year. The firm is the latest addition to the growing companies at LBIC.
Ted Fjällman, CEO of Prokarium, said, “The company is delighted to start 2019 in our new premises at the London Bioscience Innovation Centre and Prokarium is impressed by the vibrancy of the community here. With a strong focus on hiring this year, LBIC is a great place to attract talent.”